Modality
ERT
MOA
HER2
Target
GIP-R
Pathway
RAS/MAPK
Heart Failure
Development Pipeline
Preclinical
Dec 2019
→ Apr 2029
PreclinicalCurrent
NCT04700288
1,588 pts·Heart Failure
2019-12→2029-04·Recruiting
1,588 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-013.0y awayInterim· Heart Failure
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
Preclinical
Recruit…
Catalysts
Interim
2029-04-01 · 3.0y away
Heart Failure
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04700288 | Preclinical | Heart Failure | Recruiting | 1588 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R |